Open AccessP1222: PACIFIC: BRENTUXIMAB VEDOTIN AND NIVOLUMAB ALONE AND THEN COMBINED WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN AND PREDNISONE FOR UNTREATED PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA PATIENTS
Author(s) -
Steiner R.,
Strati P.,
Flowers C.,
Neelapu S.,
Green M.,
Nastoupil L.,
Hagemeister F.,
Feng L.,
Ahmed S.,
Nair R.,
Fayad L.,
Lee H.,
Rodriguez M. A.,
Westin J.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000847752.29527.f6
Subject(s) - nivolumab , medicine , brentuximab vedotin , rituximab , lymphoma , cyclophosphamide , oncology , prednisone , vincristine , cd30 , chemotherapy , cancer , immunotherapy